Evidence map›Paper›PMID 38202070›Full record

ArticleJournal of clinical medicine2023

Platelet microRNAs as Potential Novel Biomarkers for Antiplatelet Therapy with P2Y

Karolina Gumiężna, Adrian Bednarek, Grażyna Sygitowicz, Agata Maciejak-Jastrzębska, Piotr Baruś, Jaromir Hunia, Dominika Klimczak-Tomaniak, Janusz Kochman, Marcin Grabowski, Mariusz Tomaniak

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06177587 (Multimarker Evaluation of Platelet Activity and Agregation in Patients Presenting With Acute Coronary Syndrome), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06177587 completednot on this map

Multimarker Evaluation of Platelet Activity and Agregation in Patients Presenting With Acute Coronary Syndrome: Prospective Observational Study

TypeobservationalSponsorMedical University of WarsawRan2017 to 2023Enrolled150ConditionsAcute Coronary SyndromeArmsAssesment of biomarkers in acute coronary syndromes
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Karolina GumiężnaFirst Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.ORCID 0000-0002-3423-9832
Adrian BednarekFirst Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.ORCID 0000-0002-3600-4551
Grażyna SygitowiczDepartment of Clinical Chemistry and Laboratory Diagnostics, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0002-0057-4253
Agata Maciejak-JastrzębskaDepartment of Clinical Chemistry and Laboratory Diagnostics, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0002-7654-8414
Piotr BaruśFirst Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.
Jaromir HuniaFirst Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.ORCID 0000-0003-3596-0987
Dominika Klimczak-TomaniakDepartment of Cardiology, Hypertension and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.
Janusz KochmanFirst Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.
Marcin GrabowskiFirst Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.
Mariusz TomaniakFirst Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.ORCID 0000-0001-8289-1393
Medical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT). However, the response to treatment can vary considerably. Certain platelet microRNAs (miRs) are suspected to predict DAPT response and influence platelet function. This study aimed to analyze selected miRs' expressions and compare them among patients treated with different P2Y MATERIALS AND

methodsWe recruited 79 ACS patients post-PCI treated with clopidogrel, ticagrelor, or prasugrel, along with 18 healthy volunteers. Expression levels of miR-126-3p, miR223-3p, miR-21-5p, miR-197-3p, and miR-24-3p, as well as immature platelet fraction (IPF) and ADP-induced platelet reactivity, were measured and compared between groups.

resultsAnalyses revealed significantly lower expressions of miR-126-3p, miR-223-3p, miR-21-5p, and miR-197-3p in patients treated with ticagrelor, compared to clopidogrel (fold changes from -1.43 to -1.27,

conclusionsThe identified platelet miRs hold potential as biomarkers for antiplatelet therapy. (ClinicalTrials.gov number, NCT06177587).

Indexed as

acute coronary syndromedual antiplatelet therapymicroRNAP2Y12 inhibitorsplatelet reactivity

Identifiers

PMID38202070
PMCPMC10780110
OpenAlexW4390113874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.